The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Ropivacaine Hydrochloride and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approval for the PRC entities. Ropivacaine Hydro chloride and Sodium Chloride injection is mainly used in local or regional anesthesia and acute pain management for surgery. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.29 HKD | 0.00% |
|
-0.23% | -13.16% |
07:48am | Chinese Regulator OKs SSY Group's Betahistine Mesilate Tablets for Drug Production, Registration | MT |
06:01am | SSY Group Limited Announces Update on Product Development | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.16% | 1.63B | |
+62.87% | 856B | |
+38.95% | 631B | |
-3.87% | 359B | |
+15.98% | 325B | |
+8.92% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.64% | 177B | |
+1.95% | 165B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China